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Abstract
Incentives play a role in introducing health-related benefits,Background: 
but no interventions using mixed incentives, i.e. a combination of individual
and group incentives, have been tested in individuals with type 2 diabetes
mellitus (T2DM). We evaluated the feasibility of implementing individual-
and mixed-incentives, with and without a supportive partner, on glycated
haemoglobin (HbA1c) control and weight loss among patients with T2DM.
 This is a feasibility, sex-stratified, single-blinded, randomizedMethods:
controlled study in individuals with T2DM. All participants received diabetes
education and tailored goal setting for weight and glycated haemoglobin
(HbA1c). Participants were randomly assigned into three arms: individual
incentives (Arm 1), mixed incentives-altruism (Arm 2), and mixed
incentives-cooperation (Arm 3). Participants were accompanied by a
diabetes educator every other week to monitor targets, and the intervention
period lasted 3 months. The primary outcome was the change in HbA1c at
3 months from baseline. Weight and change body mass index (BMI) were
considered as secondary outcomes.
Out of 783 patients screened, a total of 54 participants, 18 perResults: 
study arm, were enrolled and 44 (82%) completed the 3-month follow-up.
Mean baseline HbA1c values were 8.5%, 7.9% and 8.2% in Arm 1, Arm 2,
and Arm 3, respectively. At 3 months, participants in all three study arms
showed reductions in HbA1c ranging from -0.9% in Arm 2 to -1.4% in Arm
1. Weight and BMI also showed reductions.
Individual and mixed cash incentives show importantConclusions: 
reductions in HbA1c, weight and BMI in patients with type 2 diabetes
mellitus after 3 months.  Recruitment and uptake of the intervention were
successfully accomplished demonstrating feasibility to conduct larger
effectiveness studies to test individual and mixed economic incentives for
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 effectiveness studies to test individual and mixed economic incentives for
diabetes management.
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Introduction
Evidence indicates that there are major benefits to be achieved 
by preventive care among patients with diabetes1–4, yet adherence 
to healthy behaviors and pharmacological treatment remains a 
challenge worldwide5–8. Non-monetary and monetary rewards 
may play a role in introducing health-related benefits by 
incentivizing behavior changes among individuals with type 2 
diabetes mellitus9. Whilst some have explored the effect of 
monetary incentives on certain behaviors, very few studies 
have evaluated the efficacy of cash rewards for patients with 
diabetes10. One randomized controlled trial utilizing cash rewards 
in African American veterans with poor glycaemic control 
found that, at six months, the group assigned to cash rewards 
slightly improved HbA1c, with a non-significant mean reduction 
in HbA1c from 9.5% to 9.1%11.
Most of the studies to date have considered an individual- 
based approach towards motivation and incentivization, but 
these have limitations12–14. Behavioral economics theory, how-
ever, suggests that group incentives, or mixed rewards, could 
outperform individual incentives due to cooperation15,16. Coop-
eration refers to a supportive action that happens between two 
“equals” doing something to achieve a common goal or 
mutual benefit17. Unlike “helping”, cooperation is an exchange 
between “equal” group members and it is opposed to compet-
ing and acting in a selfish manner18. Altruism on the other hand 
is a helpful act “carried out in the absence of obvious tangible 
rewards for the helper.”17 Altruism lies at the opposite end of 
competition. Testing mixed or group-based approaches for 
diabetes prevention or management is relatively new, and some 
studies are being conducted10,19.
Owing to the limitations of individual-based incentivization 
strategies9, this study was designed to evaluate the feasibility of 
implementing individual- and mixed-incentives, with and with-
out a “supportive” partner, on glycated haemoglobin (HbA1c) 
control and weight loss among patients with type 2 diabe-
tes mellitus. These interventions were anticipated to promote 
positive lifestyle changes, including knowledge about diabetes 
self-management, diet changes and increased physical activity. 
Additional exploratory analyses included modelling the change 
of continuous variables using repeated measurements over 
the study period; and, subgroup analyses according to the number 
of appointments completed (weekly over a 6-week period), 
and by early success in terms of number of payments provided 
in the first two appointments.
Methods
Trial design
Feasibility trial, we followed the CONSORT 2010 statement 
extension for randomized pilot and feasibility trials20. This study 
was a single-centre, sex-stratified, with balanced randomiza-
tion [1:1:1], single-blinded, non-pharmacological, parallel arm 
randomized controlled study. The intervention period lasted 
3 months. Protocol and CONSORT checklist are provided as 
Supplementary File 1 and Supplementary File 2.
Formative research
Our formative research was oriented to improve understanding 
of the challenges of living with and managing type 2 diabetes 
mellitus, the opinion of diabetic patients about a cash reward 
program and the social support they have. We conducted (1) a 
questionnaire with 100 patients with diabetes from the same 
hospital as the trial was going to be conducted21, and (2) 20 
in-depth interviews among patients with similar characteristics22. 
The questionnaires helped us determine a reasonable amount 
for the cash rewards, which ended up being 80 PEN if the 
participant lost one kilogram after two weeks, approximately 
10% of minimum wage (Peru’s minimum salary wage for 
year 2017 was 850 PEN/~$264 USD), and 400 PEN (~$124 
USD) if the HbA1c was reduced by 1% or more after 3 months. 
Through the qualitative interviews, we were also able to better 
understand the role of the family in diabetes management, which 
meant it was feasible to ask for a cooperative partner for the 
trial, and that most (83%) would choose their spouse or partner 
and 23% would choose their children. During this formative phase 
we also learned that 42% of participants had tried to lose weight at 
least once since their diagnosis of diabetes.
Participants and setting
Patients attending the outpatient clinic of the endocrinology 
service from Hospital Nacional Arzobispo Loayza were 
approached and invited into the study from July to October 2016 
(15 weeks). This hospital is located in Lima, Peru’s capital, and 
is one of the national tertiary hospitals from the Ministry of 
Health, serving low- to medium-income population. There were 
783 people assessed for eligibility.
Subjects, irrespective of their HbA1c levels, (1) with a diagnosis 
of type 2 diabetes mellitus, (2) aged 18–70 years old, (3) a body 
mass index (BMI) 25-39.9 kg/m2, (4) without diabetes-related 
complications, i.e. blindness, amputations, foot ulcers or being 
on dialysis, (5) not receiving pharmacotherapy for weight loss or 
corticosteroids, (6) not serving as companion/team support for 
another participant in the trial, and (7) with the ability to 
provide informed consent, were considered eligible for the 
study. Exclusion criteria were pregnancy status and having a 
diagnosis of cancer or other serious comorbidity.
To be eligible as a partner for the participant with diabetes, 
individuals were to be 18–70 years old, available and committed 
to supporting the participant in achieving their goals during the 
intervention, without a physical or mental impairment that 
prevented helping the participant to improve their disease 
management, and able to provide informed consent.
Fieldwork procedures
Fieldworkers explained the study to potential participants. If the 
patient was eligible, the fieldworker explained the procedures 
and intervention, and gave a copy of the informed consent form, 
and asked him/her to come back with their potential partner to 
explain and invite them to join the study. Once they returned, 
written informed consent was obtained from the two of them. If 
the participant was at the recruitment facility with their potential 
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partner, the fieldworkers explained the study to both and also 
applied the informed consent to the partner. Participants and their 
partners were reimbursed a fixed amount for their transportation 
costs to attend the appointments.
After recruitment, participants were interviewed by a trained 
fieldworker to complete a baseline questionnaire (Supplemen-
tary File 3), including information related to socio-demographic 
information, co-morbidities, characteristics about diabetes care, 
perception of diabetes23, and depression symptoms (Patients 
Health Questionnaire [PHQ-9]). Additionally, information from 
the participant’s partner was also collected, including socio- 
demographics, physical activity and willingness to help their 
partner. During the appointments with the diabetes educator, the 
participants’ weight, knowledge about diabetes self-management24, 
diet, and physical activity were recorded.
At the end of the intervention the same baseline question-
naire was applied. Also, all participants that had a companion 
support answered five questions assessing the perceived role 
they felt their partner played in improving their diet, increasing 
physical activity, and overall diabetes management and weight- 
loss intervention goals.
HbA1c was measured using high-performance liquid chroma-
tography (D10, BioRad, Munich, Germany), traceable to the 
Diabetes Control and Complications Trial reference study as 
certified by the National Glycohemoglobin Standardization 
Program. All samples were analyzed in a single facility, and, 
for quality assurance, the quality of assays was checked with 
regular external standards and internal duplicate assays and 
monitored by BioRad.
Upon completion of the trial, 29 individuals (17 participants 
and 12 partners) were selected for in-depth interviews focused 
on their experience participating in this cash rewards program. 
All interviews were transcribed verbatim and entered into 
qualitative analysis software (ATLAS.ti 8.0, Scientific Soft-
ware Development GmbH, Berlin, Germany) using a predefined 
set of codes developed from the themes of the interview guide, 
which addressed three aspects of the intervention: i) perspective 
regarding the economic incentive; ii) perspective regarding 
diabetes education received; and iii) the perspective regarding 
the support received by his chosen companion for the interven-
tion (only for participants randomized to arms 2 and 3). On the 
other hand, the interview guides elaborated for the companions 
addressed two aspects of the intervention: i) perspective of the 
companions regarding the economic incentive; and ii) perspec-
tive regarding the support provided to the participant. Data from 
each code was then organized in matrices and summaries for 
each code were produced as well as an identification of the key 
quotes given by participants.
Intervention
This study explored the role of cash rewards, with or without 
a “supportive” partner, in changing the behavior of individuals 
with type 2 diabetes mellitus, specifically by promoting healthy 
lifestyles through tailored nutritional advice, delivered by a 
diabetes educator, attached to individual goal-setting with cash 
rewards. Both actions were expected to contribute to achieve 
weight and HbA1c targets. All participants received diabetes 
education and tailored goal setting for weight and HbA1c. 
Participants were randomly assigned into three different inter-
vention arms: Arm 1, individual incentives, i.e. the cash 
rewards for the patient if the goals were achieved; Arm 2, mixed 
incentives-altruism, patient had a partner but cash rewards 
were for the patient; and, Arm 3, mixed incentives-cooperation, 
where participants had a partner but the cash was given to both 
the patient and the partner in a ratio of 50%-50%.
Diabetes education. Diabetes education was provided by a 
nutritionist with previous experience in weight management for 
people with diabetes. In the introductory meeting, the diabetes 
educator explained to the participants all the procedures, 
including details of the number of sessions, and the amount of 
money they will receive if they met the target weight. Depending 
on the study arm allocation, the diabetes educator also explained 
whether the participant needed a partner and whether the 
money was going to be only given to the participant or to 
both, the participant and the partner. Participants received a 
manual with information about diabetes management with 
a tailored weight loss plan and the bi-weekly goals. Each 
participant was offered up to seven follow-up sessions with the 
diabetes educator, every 2 weeks, plus a final session, thus 
totaling up to nine one-to-one interactions during the trial, 
provided that the participant attended all of their meetings. 
One section of the manual included a logbook to register their 
challenges regarding introducing changes in diet and physical 
activity, as well as any questions they would like to ask the 
diabetes educator in the following session. The information 
from this logbook provided the starting point for conversations 
with the diabetes educator during the follow-up sessions, every 
2 weeks. Recruitment of participants was done in a staggered 
manner to ensure the diabetes educator did not have a high 
concentration of patients in one single week. Thus, there was a 
close coordination between the fieldworker scheduling the first 
appointment and the diabetes educator who was already seeing 
participants on a bi-weekly basis, by sharing a Google Docs 
spreadsheet were both aware of the slots available.
Goal setting. To determine eligibility for receiving a cash 
reward, three goals were pre-specified: (1) Weight loss, 80 PEN 
($25 USD) if the participant lost one kilogram over a period 
of two weeks. These goals were reset based on the most recent 
weight result, (2) HbA1c level, 200 PEN ($62 USD) if the 
participant achieved, at the end of the study, a decrease of 
<1% compared to their baseline level, and (3) HbA1c level and 
control, 400 PEN ($124 USD) if the participant achieved, at 
the end of the study, a decrease ≥1% of A1c or reached levels 
of A1c ≤6.5% compared to their baseline level. At the end of 
the study, targets for weight loss and HbA1c were evaluated 
independently, i.e. participants could receive more than one 
reward provided that each independent target was achieved.
Partner support. In Arms 2 and 3 of the study, each participant 
had a partner that received information about diabetes care in 
the introductory meeting, and a brochure to guide and support 
the treatment process of the participant. The activities of the 
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partner were recorded in the case logs bi-weekly, and they were 
offered to join the follow-up sessions with the patient, every 
2 weeks, but these were not compulsory. It was only compulsory 
to attend the first and at last follow-up session.
Recipient of the cash rewards. Two strategies were consid-
ered as to who would be the recipients of the rewards. In Arm 1 
(individual) and Arm 2 (mixed-altruism) the reward was pro-
vided to the participant. It was up to the participant to share (or 
not) the reward with their partner. In contrast, in Arm 3 (mixed- 
cooperation) the reward had to be shared, i.e. the participant 
and their partner received 50% of the cash reward each.
In order to remove any income effect within the household, 
the nominal size of the cash provided was the same in all arms, 
indeed the cash per-capita was lower in a study arms 2 and 3.
Outcomes
Primary and secondary outcomes. The primary outcome was the 
change in HbA1c at 3 months from baseline. Weight and change 
body mass index (BMI) were considered as secondary outcomes, 
specifically the change at 3 months from baseline.
Intermediate outcomes. The intervention were anticipated to 
promote changes in three indicators, namely knowledge about 
diabetes self-management, diet, and physical activity.
Risk factors. The profile of risk factors were obtained from 
responses to the following questions: Alcohol: In the last year, 
how often did you drink alcohol beverages? (Never vs. ≤1/month, 
2-4/month, 2-3/week or >4/week). Smoking: Do you smoke 
at least one cigarette per day? (Yes vs. No). Walking: During 
the week, how often do you walk at least 30 min? (>5 days, 4-5 
days, 2-3 days vs. ≤1 day). Fruit intake: How often you eat fruit? 
One portion of fruit is one fresh fruit, or a glass of juice made 
out of fresh fruit, or 1 cup of fresh fruit chopped (>3, 2-3, 1 vs. 
<1 portions per day). Vegetable intake: How often do you eat 
vegetables? One portion of vegetables equals one cup with 
vegetables in any presentation or preparation: crude, cooked, 
steamed, stir fried, or grilled (>3, 2-3, 1 vs. <1 portions per day).
Sample size
Being a feasibility study, a formal sample size calculation was 
not performed. The researchers aimed to enroll 54 participants, 
18 participants per study arm, over a 3-month period because 
it was considered this would be a large enough sample to 
gather information about the practicalities of delivering 
incentive-oriented diabetes self-management strategies that would 
impact HbA1c in patients with type 2 diabetes mellitus. As such, 
the successful completion of this study would inform about 
recruitment, uptake, and attrition rates as well as engagement with 
the intervention.
Randomization
Randomization was conducted as per CONSORT criteria20. 
All participants were randomly assigned (1:1:1) to receive one 
of the three interventions using a computer-generated list of 
numbers. Randomization was stratified by sex (female:male 
ratio of 2:1), and within each stratum, the randomization process 
involved blocking with block size of 6. For allocation con-
cealment, participants were randomized using sequentially 
numbered, opaque, sealed envelopes. The sealed envelope was 
assigned after the patient had been recruited and all baseline 
measurements were completed. The random allocation sequence 
was generated by one researcher. This researcher was not 
involved in the fieldwork activities of the trial. A fieldworker was 
responsible of participants’ recruitment and taking baseline 
information. The diabetes educator was not involved in the 
randomization process. The diabetes educator was responsible 
for weighing participants and to provide the cash rewards to 
participants, the participants and the diabetes educator were not 
blind to the intervention. Physicians, other care providers and 
researchers were blinded to the study group.
Analytical methods
All analyses were conducted with STATA V.13.0 (StataCorp, 
College Station, TX, USA). Descriptive analyses, describing 
means and frequencies were conducted. Following trial rec-
ommendations, no formal statistical testing for comparison of 
baseline data was pursued25,26. Differences in HbA1c, weight, and 
BMI were estimated using 3-month and baseline information, 
and comparisons were conducted using t-paired test within the 
same study arm, and Student’s t-test between arms using the 
Arm 1 as the reference. Analysis of intermediate outcomes and 
subgroups according to the number of appointment completed 
(split into two group using the median) and the number of 
payments provided in the first two appointments (0, 1, and 
2) were conducted using the same tests. Finally, linear mixed 
models with a random intercept were used to assess changes of 
weight, BMI, and diabetes self-management values as continuous 
variables using the information captured every 2 weeks.
Ethical approval
The study protocol was reviewed and approved by the ethics 
committee from the Hospital Nacional Arzobispo Loayza, in 
Lima, Peru. The formative research received ethical approval 
from both the Universidad Peruana Cayetano Heredia and 
Hospital Nacional Arzobispo Loayza.
Results
Participants characteristics
A total of 783 participants were screened, and 54, 18 per study 
arm, were enrolled. Of them, 44 (82%) completed the 3-month 
follow-up (Figure 1). The baseline demographic and clinical 
characteristics for each study group are shown in Table 1. The 
participants’ mean age was 55 years, 36 (67%) were females, 
and half of all participants reported being employed. The 
majority of participant’s family income was <$500 USD per 
month, and the participants were not the major contributors 
to it.
The household’s average size was around 5 people, and more 
than half of participants lived with a partner. The average 
duration of the diagnosis of diabetes was 6.6 years, and large 
proportions indicated fair to very good levels of self-reported 
health. Most patients with diabetes were on oral drugs, some 
already report foot and renal diabetes complications, and 
hypertension was the most common comorbidity reported.
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Figure 1. Flowchart of study participants.
There were 36 participant partners, with a mean age of 44.9 years 
(SD 16.8); 61.1% were female. The role of partners was fulfilled 
by a spouse (33.3%), offspring (33.3%), friends (13.9%), siblings 
(5.6%), and the remaining (13.9%) were other relatives such as 
mother, grandchildren, cousin or father.
Primary and secondary outcomes at 3 months
Mean baseline HbA1c values were 8.5%, 7.9% and 8.2% in 
Arm 1, Arm 2 and Arm 3, respectively. At 3 months and 
relative to their baseline levels, participants in all three study arms 
showed reductions in HbA1c ranging from -0.9 in Arm 2 to -1.4 
in Arm 1 (Table 2). Weight and BMI also showed reductions, and 
these were more pronounced in Arm 1.
Intermediary outcomes at 3 months
There was evidence of effect of the intervention on diabetes 
self-management, diet and physical activity when comparing 
3-month and baseline assessments, especially in Arm 1 
(Supplementary File 4-Supplementary Table 1).
Subgroup analysis
Data from all study participants were pooled to generate subgroups 
according to the number of appointments completed and by early 
success in terms of number of payments provided in the first two 
appointments (Table 3).
In terms of the primary outcome, those who completed a 
higher number of appointments had a significant reduction 
of 1.2% in HbA1c levels at 3 months. On the other hand, those 
participants who were successful in receiving at least one 
cash reward in the first two appointments were more likely to 
achieve reductions in HbA1c, nearly 1 to 2 units lower compared 
to their baseline levels.
Weight showed more marked reductions as per subgroups 
analysis. Those who completed a higher number of appointments 
had, on average, reductions of up to 2 kg, compared to those in 
the lower range of appointments completed, who only showed 
reductions in the order of 0.3 kg relative to their baseline 
values. In addition, those who were highly successful securing 
two cash rewards in the first two visits had an average reduction 
of 4.5 kg, three times higher than those who only received one 
cash reward, and these two groups had more marked reductions 
in weight than those who did not receive a cash reward in their 
first two appointments.
Exploratory analysis: change in indicators every 2 weeks
Participants in Arm 1 showed gradual changes in the desired 
direction of benefit in all of these indicators. Weight reduc-
tions of 1 kg were observed at 2 weeks, reductions of up to 2 kg 
between week 4 to week 8, and >2 kg by week 10. Diabetes self-
management scores also increased, almost doubling towards 
Enrollment
Allocation
Lost to follow-up (n = 4):
Other commitments (n = 2); travel
(n = 1); intervention (1)
Lost to follow-up (n = 3):
Other commitments (n = 2); not
reached by phone (n = 1)
Analysed for weight (n = 14)
Analysed for HbA1c (n = 13)
Analysed for weight (n = 15)
Analysed for HbA1c (n = 13)
Analysed for weight (n = 15)
Analysed for HbA1c (n = 14)
Lost to follow-up (n = 3):
Travel (n = 1); not reached by
phone (n = 2)
Allocated to intervention 3 (n = 18)
Assessed for eligiblity (n = 783)
Excluded (n = 705)
Not eligible (n = 192)
Refused (n = 29)
Others (n = 2)
Did not attend baseline assessment
  (n = 84)
Declined screening (n = 398)
Received allocated intervention
  (n = 18)
Allocated to intervention 2 (n = 18)
Received allocated intervention
  (n = 18)
Allocated to intervention 1 (n = 18)
Received allocated intervention
  (n = 18)
Follow-Up
Analysis
Randomized (n = 54)
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Table 1. Baseline demographic and clinical characteristics.
Arm 1  
Individual  
(n=18)
Arm 2  
Mixed Altruism 
(n=18)
Arm 3  
Mixed Cooperation 
(n=18)
Sociodemographic profile
Female 12/18 (67%) 12/18 (67%) 12/18 (67%)
Age (years), mean ± SD 54.7 ± 9.8 55.5 ± 9.8 54.2 ± 7.6
Education
    Primary level or lower 4/18 (22%) 3/18 (17%) 2/18 (11%)
    Primary to secondary level 5/18 (28%) 10/18 (56%) 8/18 (44%)
    Secondary level or higher 9/18 (50%) 5/18 (28%) 8/18 (44%)
Occupation
   Employed 8/18 (44%) 9/18 (50%) 9/18 (50%)
   Unemployed 5/18 (28%) 2/18 (11%) 2/18 (11%)
   Housewife 5/18 (28%) 7/18 (39%) 7/18 (39%)
Monthly income†
   <850 PEN (<$264 USD) 3/16 (19%) 5/16 (31%) 6/15 (40%)
   850-1,500 PEN ($264-$465 USD) 10/16 (62%) 7/16 (44%) 4/15 (27%)
   >1,500 PEN (>$465 USD) 3/16 (19%) 4/16 (25%) 5/15 (33%)
Highest contribution to household’s income (yes) 8/18 (44%) 5/18 (28%) 6/18 (33%)
Living with a partner (yes) 11/18 (61%) 10/18 (56%) 15/18 (83%)
Household size (number of people), mean ± SD 5.4 ± 4.2 4.2 ± 2.1 4.8 ± 2.1
Diabetes-related profile
Time of diabetes diagnosis (years), mean ± SD 6.6 ± 5.8 7.4 ± 8.4 5.9 ± 3.8
Self-reported health (very good, good, fair)* 14/15 (93%) 16/17 (94%) 13/18 (72%)
Had HbA1c measured in the last 3 months (yes) 11/17 (65%) 11/16 (69%) 12/18 (67%)
Pharmacological treatment
   Oral hypoglycemic drugs 12/17 (71%) 11/17 (64%) 17/18 (94%)
   Insulin 1/17 (6%) 3/17 (18%) 0/18 (0%)
   Both 4/17 (23%) 3/17 (18%) 1/18 (6%)
Has diabetes complications
   Eye problems 11/18 (61%) 13/18 (72%) 13/18 (72%)
   Foot ulcers 2/18 (11%) 2/18 (11%) 0/18 (0%)
   Renal problems or dialysis 5/18 (28%) 3/18 (17%) 3/18 (17%)
Health-related profile
Comorbidities
   Hypertension 5/18 (28%) 5/18 (28%) 4/18 (22%)
   Stroke 1/18 (6%) 2/18 (11%) 1/18 (6%)
   Depression (PHQ-9 >14) 0/18 (0%) 1/18 (6%) 2/18 (11%)
Lifestyle and behavioral risk factors 
   Alcohol consumption (never, last 12 months) 8/18 (44%) 7/18 (39%) 7/18 (39%)
   Cigarette smoking (yes, at least one per day) 2/18 (11%) 1/18 (6%) 3/18 (17%)
   Walking 30 min (≤1 day per week) 7/18 (39%) 6/18 (33%) 5/18 (28%)
   Fruit intake (<1 portion per day) 8/18 (44%) 3/18 (17%) 2/18 (11%)
   Vegetable intake (<1 portion per day) 4/18 (22%) 3/18 (17%) 3/18 (17%)
All values presented correspond to n (%), unless otherwise stated.
†Peru minimum salary wage for year 2017 was 850 PEN, the category used for monthly income. Average exchange rate 
for year 2017 was 1 PEN = 0.31 USD. *Self-reported health, the corresponding figures (not shown) belong to poor or very 
poor categories. 
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Table 2. Primary and secondary outcomes at baseline and 3-month results, by study arms.
Arm 1 Individual Arm 2 Mixed Altruism
Arm 3 Mixed 
Cooperation
Arm 2 vs.  
Arm 1 (p-value)
Arm 3 vs. 
Arm 1  
(p-value)
Primary outcome
HbA1c (%)
   Baseline 8.5 ± 2.2 7.9 ± 3.1 8.2 ± 2.1 0.99 0.99
   3 months 6.9 ± 1.7 7.2 ± 1.6 7.1 ± 1.7 0.99 0.99
   Δ (3-mo vs 
baseline) -1.4 ± 1.4 -0.9 ± 1.2 -1.1 ± 1.6 0.05 0.05
Secondary 
outcomes
Weight (Kg)
   Baseline 76.9 ± 10.7 84.5 ± 17.4 85.1 ± 22.3 0.59 0.48
   3 months 72.6 ± 11.0 82.2 ± 17.2 84.7 ± 22.7 0.45 0.20
   Δ (3-mo vs 
baseline) -2.9 ± 2.2 -0.4 ± 2.5 -0.4 ± 3.0 0.04 0.03
BMI (Kg/m2)
   Baseline 33.1 ± 4.8 34.6 ± 6.0 36.1 ± 10.1 0.99 0.67
   3 months 31.6 ± 5.2 33.8 ± 5.7 36.0 ± 9.8 0.99 0.31
   Δ (3-mo vs 
baseline) -1.2 ± 0.9 -0.2 ± 1.0 -0.2 ± 1.4 0.05 0.05
Values in bold are those significant (p<0.05) when comparing difference between 3-month and baseline 
assessment (within each arm).
Table 3. Primary and secondary outcomes at baseline and 3-month results, by study’s subgroups.
Subgroups by number of 
appointments completed
Subgroups by number of payments provided in 
the first two appointments 
Lower Higher p-value* 0 1 2 p-value*
N = 24 N = 30 N = 24 N = 21 N = 9 
Primary outcome
HbA1c (%)
   Baseline 8.0 ± 3.0 8.3 ± 2.0 0.66 7.9 ± 3.1 9.0 ± 1.9 7.1 ± 1.1 0.11
   3 months 6.8 ± 1.3 7.1 ± 1.7 0.64 7.5 ± 2.1 7.3 ± 1.3 6.0 ± 0.4 0.09
   Δ (3-mo vs 
baseline) -0.8 ± 1.5 -1.2 ± 1.4 0.49 -0.6 ± 1.6 -1.8 ± 1.3 -1.0 ± 0.9 0.07
Secondary 
outcomes
Weight (Kg)
   Baseline 85.2 ± 16.9 79.7 ± 17.9 0.26 78.3 ± 16.8 83.4 ± 11.8 89.6 ± 27.6 0.23
   3 months 84.2 ± 19.2 77.7 ± 17.4 0.28 74.8 ± 15.7 82.7 ± 13.9 85.1 ± 26.9 0.27
   Δ (3-mo vs 
baseline) 0.3 ± 1.9 -2.0 ± 2.8 0.009 0.6 ± 1.9 -1.6 ± 2.1 -4.5 ± 2.3 <0.001
BMI (Kg/m2)
   Baseline 35.5 ± 6.4 33.9 ± 8.0 0.42 33.5 ± 6.0 33.8 ± 4.2 39.3 ± 13.2 0.10
   3 months 35.5 ± 6.7 33.0 ± 7.5 0.29 32.4 ± 5.1 33.4 ± 5.1 37.3 ± 12.6 0.25
   Δ (3-mo vs 
baseline) 0.1 ± 0.8 -0.9 ± 1.2 0.01 0.2 ± 0.8 -0.7 ± 0.8 -2.0 ± 1.1 <0.001
Values in bold are those significant (p<0.05) when comparing difference between 3-month and baseline assessment (within 
each arm). * p-values in the columns are for comparisons between subgroups.
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the end of study’s intervention period (Supplementary File 4- 
Supplementary Table 2).
No changes in diabetes self-management scores were noted 
in Arms 2 or 3. In these arms, only changes in weight and BMI 
were observed, but these became evident only after 10 weeks 
(Arm 2) and 6 weeks (Arm 3) from baseline. Changes in weight 
achieved towards the end of the study period were in the order of 
reductions of 2.3-2.4 Kg, equivalent to reductions of ~1 unit of 
BMI.
The partner support
Of the 27 participants that answered the final questionnaire and 
had partner support, 23 (85%) of participants assessed that their 
partners’ support was “a lot” or “fair” towards achieving an 
improved diet. Similar results, “a lot” or “fair”, were also 
reported for increasing their physical activity (20/27, 74%), 
adhering to their medication regime (23/27, 85%), overall diabe-
tes management (23/27, 85%), and achieving weight-loss goals 
(23/27, 85%).
When asked to explain these answers, participants said that 
their supportive partners motivated them either for taking care 
of their diet or for doing exercise. Other partners reminded 
patients of their medication, prepared diabetic-appropriate meals, 
went on walks together, accompanied to their appointments 
or told them what they could or could not eat. Overall, participants 
felt supported by their partners.
In the in-depth interviews, most participants stated that they 
liked that they were given the freedom to choose the partner 
and that their choice was based on the high level of trust in that 
person, which, in turn, enabled a more constant interaction 
between them. Such interactions revolved around talking about 
the recommendations provided by the diabetes educator and 
the strategies to put them into practice. Having a partner involved 
also facilitated the engagement with other family members 
who were informed about the disease and the intervention.
On the other hand, interviewed partners stated that the 
intervention helped them improve their support to the person 
with diabetes by increasing their (partner) knowledge about the 
disease and having more tools to help patients lose weight and 
manage the disease.
Harms
No harms or unintended effects in each group were observed.
Discussion
This study was designed to evaluate the feasibility of imple-
menting individual and mixed cash rewards on HbA1c and 
weight loss among patients with type 2 diabetes mellitus. After 
completion of the 3-month intervention, notable reductions 
were observed in HbA1c, weight and BMI, and also in some of 
the intermediate and self-reported outcomes. Subgroup analy-
sis confirm reductions in weight and BMI among those who 
complete a higher number of appointments and more clearly 
among those who achieve early success, i.e. those who were 
eligible to receive a cash reward during their first two 
appointments.
Contrasting with the effect of oral antidiabetic drugs, which 
lowers HbA1c in the order of 0.5%-1.25%27, our results, derived 
from a complex intervention relying on diabetes education with 
tailored goal-setting with or without group (partner) support, 
showed reductions in HbA1c of similar magnitude to those 
achieved with pharmacological treatment. The accomplishment 
of recruitment and conduction of this study, together with the 
uptake of the intervention by the study participants, demonstrate 
the feasibility of conducting larger effectiveness studies using 
individual incentives and mixed incentives involving carers for 
supporting diabetes management.
Our study contributes with ongoing debates about the challenges 
of lifestyle modification, a cornerstone for diabetes management 
and control7,28,29. This study provides pragmatic insights into 
two of the top-ten research priorities established by people 
living with diabetes and their carers, i.e. “what is the best way 
to encourage people with type 2 diabetes mellitus, whoever they 
are and wherever they live, to self-manage their condition, and 
how should it be delivered?” and “how can people with type 
2 diabetes mellitus be supported to make lifestyle changes to 
help them to manage their condition, how effective are these 
lifestyle changes, and what stops them from working?”30 The 
participation of companion partners in our study elucidated that 
although participants assessed that the support was important, 
the provision of family support for people with chronic condi-
tions is not free of problems. As described elsewhere, families can 
sometimes undermine lifestyle changes or self-management 
when they have a poor understanding of the disease or when 
their “supportive style” is perceived as nagging by patients22.
Mixing social support with cash rewards aims to overcome 
the limitations of the individual cash rewards approaches. For 
example, sustaining complex tasks may place the individual 
under pressure or feel negatively motivated because of the 
burden associated with the management of diabetes31–34. In 
this sense, our mixed incentives arms tried to explore different 
concepts. Arm 2 was purely based on altruism, and, in a way, 
the reward was similar to Arm 1, the individual incentives. On 
the contrary, Arm 3 was specifically designed to test cooperation 
and the effort directly compensated both parties. Interestingly, 
when designing a complex intervention, and as shown by our 
results, engaging participants with earlier “gains” such receiving 
a cash reward during their first two appointments, and receiv-
ing a higher dose of the intervention expressed by the 
completion of a higher number of appointments signal to 
improvements HbA1c, between 1 and 2% lower, and weight and 
BMI at 3 months. This observation is in line with the behavio-
ral literature that has identified that small but tangible rewards, 
delivered with high frequency, can aid engagement with complex 
tasks9.
In minority groups from high-income settings, culturally 
appropriate interventions appear to have a more pronounced 
effect in reducing HbA1c levels compared to usual care, reported 
in the order of reductions of 0.5 units at 3 months35. Our study 
showed much higher, even doubling, effect sizes over the same 
period of time, thus indicating promising scenarios for further 
HbA1c control. Our pilot was not designed to formally test 
comparisons between study arms, yet the results obtained were 
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in the expected direction and improvements were observed after 
the completion of the 3-month study period in all primary and 
secondary outcomes, both within study arms and between arms. 
Also, the rationale for the selection of the main outcomes was 
based in that they can be objectively ascertained and are integral 
part of diabetes management6,28. We express caution with the 
interpretation of results as it cannot be ascertained whether 
the changes in primary or secondary outcomes are due to the 
effect of the intervention in a given study arm. If anything, 
changes were observed in reducing HbA1c levels and important 
lessons were obtained for the practicalities of conducting larger 
studies using mixed incentives and enabling activities between 
patients, companion supports and diabetes educators.
Various systematic reviews have covered the effect of incentives 
and cash rewards on lifestyle behaviours36–39, but none of these 
reviews evaluated its impact on type 2 diabetes mellitus. Other 
trials have explored or are exploring the effect of individual 
versus group financial incentives for reducing weight loss in 
high-income settings, with rewards up to $520 USD19,40, much 
larger than the ones provided in our study. In the UK, Relton 
et al.41 assessed an NHS-commissioned financial incentive 
weight loss program, aiming to reduce between 6.8 to 22.7 kg in 
3 to 7 months, with incentives ranging from £70 to £425. They 
found that 40% achieved clinically significant weight loss41. 
Whilst there is not direct comparability between the type or 
intensity of intervention, in our study we expand upon these 
experiences by showing the feasibility of reducing levels of 
HbA1c.
One of the strengths of the study is the ability to accommo-
date an incentive-based strategy together with an effective goal- 
setting approach for patients with uncontrolled diabetes in 
low-resource settings and observing benefits in objective 
indicators such as HbA1c and weight reductions. Also, our 
formative phase explored and guided the characterization of 
the size of the cash reward, a detail usually missing in the cash 
incentive literature38,42. The introduction of two different 
mixed-incentives arms affords a pragmatic understanding that 
tackling diabetes management is a task that can be absorbed and 
accommodated by both, patients and their companion support, 
and thus expanding the arsenal of strategies to deal with diabetes. 
In our study, all participants were exposed to diabetes education 
and goal setting strategies. Whilst some of the effects are 
expected to be accrued through self-determination and oppor-
tunities to deal with the burden of diabetes’ self-management, 
there is an element where face-to-face consultations are also 
needed to maintain engagement and motivation43, and as such, this 
element will need to be maintained in larger studies.
Amongst the limitations are the difficulty in measuring and 
monitoring, bi-weekly, diet and physical activity. Whilst we used 
proxies for this measurements, it is clear that introducing such 
close monitoring of lifestyle habits may introduce additional 
challenges and increase burden among study participants34, 
hence the preference for objective markers to monitor such as 
weight or HbA1c, which can be expanded to quality of life or 
utilization of health services if needed. Being a pilot study, a short-
term strategy was pursued, requiring longer study intervention 
periods, and importantly, even longer follow-up periods with-
out the intervention to study if the changes are maintained 
after the removal of the strategy. This is very important as we 
do not envisage to maintain participants under a program of 
incentivization for the long term, rather, this program is the 
medium to install and maintain the changes required for a suc-
cessful diabetes management. Future studies should convey 
larger follow-up periods, capture meaningful patient-important 
outcomes44–46, explore whether the effect is sustained after 
removing the intervention of interest, and even consider testing 
whether mixed incentives are as effective or even better than 
individual-based incentives.
Conclusions
After 3 months, our individual and mixed cash incentives 
program show important reductions in HbA1c, weight and 
BMI among patients with type 2 diabetes mellitus from low- 
income areas. Recruitment and uptake of the intervention were 
successfully accomplished, and attrition rates were not major 
hurdles, demonstrating feasibility of establishing larger efforts 
to expand the test individual or mixed monetary incentives for 
diabetes management.
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in low-resource settings. The study described is interesting and novel in using a monetary incentive to
encourage behavioral change that improves diabetes-related health outcomes. As formative research, the
work can be used to generate hypotheses and can be replicated. It offers novel work on incentive-setting
that can be valuable in many different study settings.
There are some concerns about the methods and conclusions that I suggest the authors consider.
It is not clear why there is no control group. I am interested in whether incentives for preventive care
improve upon the status quo, which is no incentive. If that question has already been thoroughly explored,
then that previous research should be described.
It would be interesting to know more about the patients' partners, such as their own health status. There
may be an association between the diabetic patient's success on the outcomes and the partner's own
health. I suggest the same questions be asked of participant's partners as the participant survey.
There are large differences across the three arms on many of the baseline characteristics because the
samples are small. For instance, the level of education is quite different across groups. Although the
groups are randomized, demographic variables can influence the stated outcomes. An example is that
incentive-related behavior is related to income and education.  
I suggest more discussion of the findings. The point is made that the study demonstrates feasibility of
larger studies, but I remain to be convinced that this intensive intervention, both in educator time and
monitoring time, is practical at a large scale except in a trial setting. Also please discuss further the
behavioral aspects of the results, including spelling out what lessons were obtained for the practicalities of
larger studies, as suggested on page 9 and 10.
The lack of additional benefit from the caregiver participation is a major finding, and a counter-intuitive
one as I would have expected stronger results due to the patient's commitment to those family and
friends. 
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There are some concerns about the methods and conclusions that I suggest the authors consider.
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 been thoroughly explored, then that previous research should be described.
. Indeed, this work may appear as incomplete at this stage, and this can beResponse #2
explained. Rather than embarking into multiple aspects of a complete study, the research team
made an open decision to focus this feasibility study in developing, packaging and delivering a
reward-based strategy. For example, we had to decide against having a control group because, as
a feasibility approach, the study will not be powered to test comparisons between the intervention
vs. control groups. Instead, we decided to take one further step and accommodate, from an
exploratory angle, groups based on altruism and cooperation. By completing this feasibility study,
we demonstrate the acceptability of the intervention to the study participants, the capacity to
deliver these interventions, and the readiness to embark into a larger full/complete randomized
controlled study.
. It would be interesting to know more about the patients' partners, such as their ownComment #3
health status. There may be an association between the diabetic patient's success on the
outcomes and the partner's own health. I suggest the same questions be asked of participant's
partners as the participant survey.
. This is a very good recommendation and one that we can accommodate in a futureResponse #3
larger study. Thank you for this suggestion!
. There are large differences across the three arms on many of the baselineComment #4
characteristics because the samples are small. For instance, the level of education is quite
different across groups. Although the groups are randomized, demographic variables can influence
the stated outcomes. An example is that incentive-related behavior is related to income and
education.  
. Correct, randomization at baseline do show imbalances, and this is because theResponse #4
study’s sample size is too small as pointed out. We are cautious with our interpretation. Indeed, in
the discussion, we express the following: “Our pilot was not designed to formally test comparisons
between study arms [...]. We express caution with the interpretation of results as it cannot be
ascertained whether the changes in primary or secondary outcomes are due to the effect of the
intervention in a given study arm. If anything, changes were observed in reducing HbA1c levels
and important lessons were obtained for the practicalities of conducting larger studies using mixed
.”incentives and enabling activities between patients, companion supports and diabetes educators
. I suggest more discussion of the findings. The point is made that the studyComment #5
demonstrates the feasibility of larger studies, but I remain to be convinced that this intensive
intervention, both in educator time and monitoring time, is practical at a large scale except in a trial
setting. Also please discuss further the behavioral aspects of the results, including spelling out
what lessons were obtained for the practicalities of larger studies, as suggested on page 9 and 10.
. We agree that this is an intensive intervention, yet its practicality will need toResponse #5
weighted against its effectiveness (which remains to be seen) and the large societal costs related
to diabetes. Two arguments can be put forward. First, today’s status quo is quite shocking, with
almost half of UK and US adults with diabetes as well as more than 90% of Peruvian patients not
meeting the recommended goals for diabetes care.  Something needs to be done. Second,[1–3]
there are recent promising results arising from the DIRECT study, conducted in the primary care
network, which has shown that diabetes remission can be achieved through intense 12-month
weight loss management program.  Whilst the intensity of the intervention is a key factor to[4, 5]
consider, there are other factors as well. If weight-loss intense strategies can direct towards people
engaging with better diet and lifestyles for longer periods, a lesser use of pharmacological
medications with its associated risks, and even diabetes remission, then the scenario will be
different. We will be able to complement this evidence, in a future study, by studying the effect of
Page 15 of 17
Wellcome Open Research 2018, 3:139 Last updated: 17 OCT 2019
 different. We will be able to complement this evidence, in a future study, by studying the effect of
individual and group-based rewards. We have expanded the discussion with these reflections.
. The lack of additional benefit from the caregiver participation is a major finding, andComment #6
a counter-intuitive one as I would have expected stronger results due to the patient's commitment
to those family and friends.
. Unfortunately, it is premature to reach to such a conclusion, we need a full largerResponse #6
study to answer such a question.
. Minor: There is no mention of how the 29 individuals were selected for in-depthComment #7
interviews.
. We aimed to select 6 participants per study arm (18 in total), and 6 partners perResponse #7
study arm (12 in total), and we managed to interview 29/30 out of the planned target. Within each
6, we selected 3 who “performed well during the intervention”, defined as those who were able to
lose 3Kg or more, and 3 others who did not. This detail has been added to the manuscript.
. Minor: The paragraph mentioning income effects is unclear.Comment #8
. We have edited this paragraph, which now reads, “Response #8 We kept the size of the reward
equal between the treatment groups to avoid an income effect at the household level, i.e. the
reward size was the same across all study arms regardless of the involvement of the partner
.” To explain further, a participant in the study Arm 1 would have received a pre-specifiedsupport
amount for each target accomplished, whereas in study Arm 3 the same amount would have to be
shared between the participant and his partner. In the latter scenario, this approach implies a lower
reward per each individual (the patient and his partner). The alternative scenario would have been
to offer the same amount for each individual across irrespective of their study Arm allocation,
however, the household’s of participants assigned to patient+partner would have received twice as
much as those in the individual-only Arm, generating an income effect within the household. This is
what we are trying to explain in this paragraph. If this is still confusing, we are willing to hear advice
on how best to phrase this information.
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